A Phase 1 Study of ENMD-2076 in Patients With Relapsed or Refractory Multiple Myeloma.

Trial Profile

A Phase 1 Study of ENMD-2076 in Patients With Relapsed or Refractory Multiple Myeloma.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2014

At a glance

  • Drugs ENMD 2076 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors CASI Pharmaceuticals; EntreMed
  • Most Recent Events

    • 19 Jan 2012 Actual patient number is 13 according to ClinicalTrials.gov.
    • 19 Jan 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
    • 19 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top